Aardvark Therapeutics Inc [AARD] stock is trading at $8.3, down -2.24%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AARD shares have lost -15.05% over the last week, with a monthly amount drifted -30.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aardvark Therapeutics Inc [NASDAQ: AARD] stock has seen the most recent analyst activity on June 30, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $40. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on March 10, 2025, and set its price target to $21. On March 10, 2025, Morgan Stanley initiated with a Overweight rating and assigned a price target of $29 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $50 on March 10, 2025. BofA Securities initiated its recommendation with a Buy and recommended $22 as its price target on March 10, 2025.
Aardvark Therapeutics Inc [AARD] stock has fluctuated between $4.88 and $19.58 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Aardvark Therapeutics Inc [NASDAQ: AARD] shares were valued at $8.3 at the most recent close of the market. An investor can expect a potential return of 249.4% based on the average AARD price forecast.
Analyzing the AARD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.78 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.17 points at the first support level, and at 8.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.45, and for the 2nd resistance point, it is at 8.61.
Ratios To Look Out For
For context, Aardvark Therapeutics Inc’s Current Ratio is 14.04. As well, the Quick Ratio is 14.04, while the Cash Ratio is 2.52.
Transactions by insiders
Recent insider trading involved VICKERS VENT GLB DEEP-TECH FND, Director, that happened on Aug 28 ’25 when 27691.0 shares were purchased. 10% Owner, Decheng Capital Global Life Sc completed a deal on Feb 14 ’25 to buy 1.25 million shares. Meanwhile, Chief Executive Officer Lee Tien-Li bought 16542.0 shares on Feb 14 ’25.
